Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | REN | P00797 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 3/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.41 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.40 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.40 |
| ▸ | RHOA | P61586 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3123197 | 1.00 | USP30 (0.47) | USP30POLBRENCYP3A4BRD4 | |
| SCHEMBL2850274 | 0.88 | KAT6A (0.49) | USP30POLBRENMEN1KMT2A | |
| SCHEMBL2850273 | 0.88 | KAT6A (0.49) | USP30POLBRENMEN1KMT2A | |
| SCHEMBL2846275 | 0.87 | POLB (0.45) | POLBRENCYP3A4MEN1KMT2A | |
| SCHEMBL2849948 | 0.87 | POLB (0.45) | POLBRENCYP3A4MEN1KMT2A | |
| SCHEMBL8143207 | 0.84 | REN (0.43) | USP30POLBRENCYP3A4BRD4 | |
| SCHEMBL13010324 | 0.82 | USP30 (0.44) | USP30RENCYP3A4BRD4STS | |
| SCHEMBL8145711 | 0.82 | USP30 (0.44) | USP30RENCYP3A4BRD4STS | |
| SCHEMBL970360 | 0.79 | POLB (0.51) | USP30POLBMEN1KMT2AALDH1A1 | |
| SCHEMBL970359 | 0.79 | POLB (0.51) | USP30POLBMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317697-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
| US-20100317697-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
| US-20100317697-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
| US-20100280005-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-11-04 | — | — | US | disclosed |
| US-20100179109-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-07-15 | — | — | US | disclosed |
| US-20100179109-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-07-15 | — | — | US | disclosed |
| US-20100179109-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-07-15 | — | — | US | disclosed |
| US-20100130471-A1 | Renin Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-05-27 | — | — | US | disclosed |
| US-20100130471-A1 | Renin Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-05-27 | — | — | US | disclosed |
| WO-2009096996-A1 | RENIN INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-06 | — | — | WO | disclosed |
| WO-2008124575-A1 | RENIN INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008124582-A1 | RENIN INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179109-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | USP30 2211/4885POLB 1716/4885REN 1/4885 |
| US-20100280005-A1 | Renin Inhibitors | REN, ACE, AGTR1 | USP30 2118/4885POLB 1709/4885REN 1/4885 |
| US-20100317697-A1 | Renin Inhibitors | REN, ACE, SERPINB1 | USP30 2244/4885POLB 1943/4885REN 1/4885 |
| US-20100130471-A1 | Renin Inhibitors | ACE, REN, DNPEP | USP30 740/4885POLB 1262/4885REN 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.